FDA clears Toshiba’s Aquilion RXL Edition CT system

Published on August 23, 2012 at 4:13 AM · No Comments

Offering healthcare providers a CT system designed for acute and routine imaging, Toshiba America Medical Systems, Inc. has received FDA clearance for its AquilionTM RXL Edition CT system. The Aquilion RXL reconstructs images faster and includes the latest dose reduction technologies, providing faster, safer information to physicians and patients.    

Aquilion RXL brings the most advanced radiation dose reduction technology to the 16-detector row CT system with Toshiba's Adaptive Iterative Dose Reduction 3D (AIDR 3D). AIDR 3D lowers radiation dose compared with conventional scanning, aiding clinicians in accurate diagnoses and treatment planning. It is a sophisticated algorithm designed to work in both the raw data and image data spaces, reducing noise while attempting to maintain image quality. The system also features Toshiba's NEMA XR 25 Dose Check Software which improves user awareness of the radiation dose administered to patients.

Additionally, Aquilion RXL incorporates Toshiba's sophisticated suite of SURETechnologies, increasing clinical capabilities and significantly improving productivity.

"Aquilion RXL is the ideal system for healthcare facilities looking for a safe, efficient and accurate CT system, combining performance and value for every-day imaging needs," said Satrajit Misra, senior director, CT Business Unit, Toshiba. "The integrated AIDR 3D radiation dose reduction technology creates safer exams for improved patient care."    

Source:

Toshiba America Medical Systems, Inc.        

Posted in: Device / Technology News | Healthcare News

Tags: , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen